IMO the responses speak volumes about the HC investors attitudes than the prospects for the company. Not one person was able to show a considered approach to the potential revenue or the value of the company. While no doubt having some use in remote regions, it offers less than an experienced physician with a stethescope, since it can't provide treatment. While its not a gimmick, I would suggest that the "promise" would likely exceed its actual clinical use.
Telehealth on the rise, page-271
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #